Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of NPCE is 21 and suggests 37% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell